As stated in the recently published paper by the IWG (Vargas HM et al, 2020) “The time has come to meaningfully merge nonclinical and clinical data to enable a more comprehensive, but flexible, clinical risk assessment strategy for QTc monitoring”.
As a safety pharmacology leader, your voice matters! the ICH E14/S7B Q&As are still open for comment in some regions, but not for much longer! Stakeholders from ICH Member countries/regions are encouraged to submit their comments to their respective Regulatory Authorities prior to their deadlines.
During our 2020 Virtual Annual Meeting, September 14-17, 2020, the Safety Pharmacology Society recognized the award recipients for our Translational Safety Pharmacology Publication Award and Technological Innovation Publication Award.